Drug Trial Radar · NCT06235216
Sacituzumab govitEcan in THYroid Cancers
Last checked: Nov 20, 2026Latest source record: Sep 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Sep 13, 2024
Primary completion
Dec 2027
Study completion Dec 2027
Sponsor
- Lead sponsor
- Grupo Espanol de Tumores NeuroendocrinosAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- MFAR; Gilead Sciences
- First posted
- Jan 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SETHY is a prospective, multicohort, phase II, single-arm, non-randomized, non-blinded, investigator-initiated study of sacituzumab govitecan in patients with advanced or metastatic radioactive-iodine refractory differentiated thyroid carcinoma (DTC) or anaplastic thyroid carcinoma (ATC). The main hypothesis is that treatment with sacituzumab govitecan, a anti-Trophoblast cell surface antigen 2 (TROP-2), could be an effective treatment option for patients with either differentiated and anaplastic thyroid neoplasms because TROP-2 is highly expressed at the membrane of DTC and ATC.
Conditions
- Differentiated Thyroid Cancer
- Anaplastic Thyroid Cancer
Interventions
Sacituzumab govitecanDrug
Dose of 10 mg/kg intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Throughout the study period, approximately 42 months since the inclusion of first patient
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Hospital Universitari Vall d'Hebron
Barcelona, Spain · Recruiting
Complexo Hospitalario Universitario de Ferrol
Ferrol, Spain · Not yet recruiting
Institut Catala d´Oncologia (ICO) -Hospitalet
Hospitalet de Llobregat (Barcelona), Spain · Recruiting
Hospital Clínico San Carlos
Madrid, Spain · Recruiting
Hospital Universitario la Paz
Madrid, Spain · Recruiting
Hospital Universitario Ramón y Cajal
Madrid, Spain · Not yet recruiting
MD Anderson Cancer Center Madrid
Madrid, Spain · Recruiting
Hospital General Universitario Morales Meseguer
Murcia, Spain · Recruiting
Hospital Universitario Central de Asturias
Oviedo, Spain · Recruiting
H.U. Marqués de Valdecilla
Santander, Spain · Recruiting
Hospital Universitario Miguel Servet
Zaragoza, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.